Last $43.35 USD
Change Today +0.06 / 0.14%
Volume 3.5M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:04 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Snapshot

Open
$43.08
Previous Close
$43.29
Day High
$43.58
Day Low
$42.98
52 Week High
02/18/14 - $56.73
52 Week Low
12/15/14 - $41.29
Market Cap
105.4B
Average Volume 10 Days
5.9M
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
11/5/14
P/E TM
--
Dividend
$2.45
Dividend Yield
6.12%
Current Stock Chart for GLAXOSMITHKLINE PLC-SPON ADR (GSK)

glaxosmithkline plc-spon adr (GSK) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc-spon adr (GSK) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global Vaccines, Executive Direct...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc-spon adr (GSK) Key Developments

GlaxoSmithKline Reports Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant

Agenus Inc. announced that its partner GlaxoSmithKline reported that the ZOE-50 Phase 3 study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo. HZ/su is a novel candidate vaccine that combines gE, a protein found on the varicella-zoster virus that causes shingles, with GSK's Adjuvant System, AS01B, which serves to stimulate a stronger immunological response to the vaccine. Agenus' QS-21 Stimulon adjuvant is one of the key components of AS01, which is used in other vaccine candidates undergoing clinical development. Agenus is entitled to receive royalties on potential commercial sales of HZ/su. Data from GSK's ZOE-50 study are expected to be presented at a forthcoming scientific conference and will be submitted for publication in a peer-reviewed journal.

GlaxoSmithKline Launches European Consortium for Development of New Candidate Treatment with University of Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne, and the Bernhard-Nocht Institute

GlaxoSmithKline announced the creation of a new consortium formed in partnership with researchers from University of Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne, and the Bernhard-Nocht Institute which is co-financed by the European Commission. The aim of the consortium is to boost research on a novel Ebola vaccine developed by GSK and the US National Institutes of Health. The consortium is supported by EUR 15.1 million (USD 18.8 million) granted from the European Commission through the Horizon 2020 programme aimed at helping research targeting treatments and vaccines for Ebola.

GlaxoSmithKline Announces Earnings Results for the First Half of 2014

GlaxoSmithKline announced earnings results for the first half of 2014. The company's sales in the first half of 2014 were worse than expected after revealing a turnover of 5.6 billion, down 4% from the same time last year, and core earnings down 12%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $43.35 USD +0.06

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $165.48 USD +0.18
AbbVie Inc $67.71 USD -0.21
Biogen Idec Inc $360.67 USD +6.97
Celgene Corp $117.18 USD +0.70
Novo Nordisk A/S kr265.70 DKK -0.30
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 15.7x
Price/Sales 2.7x
Price/Book 12.8x
Price/Cash Flow 15.6x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.